Sunlenca Product Label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: potentially increased levels of lenacapavir
Drug 1
Mechanism
Inhibition of CYP3A4 by atazanavir and ritonavir
Clinical Effects
Potential increase in lenacapavir adverse effects
Management
Use alternative agents
Info Source
